ugichem is developing next generation antisense drugs, called Ugimers. The “Ugimer toolkit” allows an unattainable customization of cell and organ specificity for antisense drugs to target previously inaccessible clinical pathways.
Ugimers allow overcoming the shortcomings of standard antisense chemistries or RNAi since they are not derived from natural nucleic acids. Ugimers are based on the PNA backbone and carry specific side chains enabling an organ and cell specific antisense drug development. As one result of this, Ugimers have an improved therapeutic window especially for immune cell mediated disorders such as inflammatory/autoimmune diseases, cancer and degenerative diseases.